Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: A randomized controlled trial in patients with type 2 diabetes beginning insulin therapy

Journal of Diabetes and its Complications

Volumn 20, Issue 3, 2006, Pages 145-152

  Kazda, Christof ^a   Hülstrunk, Hiltrud ^a   Helsberg, Karin ^a   Langer, Frank ^a   Forst, Thomas ^b   Hanefeld, Markolf ^c  

^a LILLY DEUTSCHLAND GMBH   (Germany)

^b Institute for Clinical Research and Development   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

HbA1c; Insulin analog; Multicenter study; Postprandial blood glucose

Indexed keywords

ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HUMALOG MIX 50; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; PHENETICILLIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DIET RESTRICTION; DRUG INDUCED HEADACHE; DYSLIPIDEMIA; FEMALE; FLU LIKE SYNDROME; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; INFECTION; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF MONITORING; STATISTICAL SIGNIFICANCE;

ADULT; AGED; BLOOD GLUCOSE; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PATIENT SATISFACTION; POSTPRANDIAL PERIOD;

EID: 33748263029     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2005.09.004     Document Type: Article

References (40)

1. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 24 Suppl. 1 (2001) S33-S43
2. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 27 Suppl. 1 (2004) S15-S35
3. Anderson Jr. J.H., Brunelle R.L., Keohane P., Koivisto V.A., Trautmann M.E., Vignati L., and DiMarchi R. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Archives of Internal Medicine 157 (1997) 1249-1255
4. Bastyr III E.J., Stuart C.A., Brodows R.G., Schwartz S., Graf C.J., Zagar A., and Robertson K.E. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. Diabetes Care 23 (2000) 1236-1241
5. Bonora E., and Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: The epidemiological evidence. Diabetologia 44 (2002) 2107-2114
6. Bruttomesso D., Pianta A., Mari A., Valerio A., Marescotti M.C., Avogaro A., Tiengo A., and Del Prato S. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 48 (1999) 99-105
7. Butler A.E., Janson J., Bonner-Weir S., Ritzel R., Rizza R.A., and Butler P.C. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52 (2003) 102-110
8. Campbell R.K., and White Jr. J.R. Insulin therapy in type 2 diabetes. Journal of the American Pharmaceutical Association (Washington, D. C.: 1996) 42 (2002) 602-611
9. DeVeciana M., Major C.A., Morgan M.A., Asrat T., Toohey J.S., Lien J.M., and Evans A.T. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. New England Journal of Medicine 333 (1995) 1237-1241
10. Feinglos M.N., Thacker C.H., English J., Bethel M.A., and Lane J.D. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care 20 (1997) 1539-1542
11. Forst T., Kunt T., Kazda C.h., Lobisch M., and Pfützner A. Die rolle der protein kinase C in der entwicklung mikrovaskulärer komplikationen des diabetes mellitus. Diabetes und Stoffwechsel 11 (2002) 62-70
12. Gastaldelli A., Ferrannini E., Miyazaki Y., Matsuda M., and DeFronzo R.A. Beta-cell dysfunction and glucose intolerance: Results from the San Antonio Metabolism (SAM) study. Diabetologia 47 (2004) 31-39
13. Gerich J.E. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Archives of Internal Medicine 163 (2003) 1306-1316
14. Hanefeld M., Fischer S., Julius U., Schulze J., Schwanebeck U., Schmechel H., Ziegelasch H.J., and Lindner J. Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11-year follow-up. Diabetologia 39 (1996) 1577-1583
15. Hanefeld M., Temelkova-Kurktschiev T., Schaper F., Henkel E., Siegert G., and Koehler C. Impaired fasting glucose is not a risk factor for atherosclerosis. Diabetic Medicine 16 (1999) 212-218
16. Hanefeld M., Koehler C., Schaper F., Fuecker K., Henkel E., and Temelkova-Kurktschiev T. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis 144 (1999) 229-335
17. Heinemann L., Linkeschova R., Rave K., Hompesch B., Sedlak M., and Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23 (2000) 644-649
18. Heise T., and Heinemann L. Rapid and long-acting analogues as an approach to improve insulin therapy: An evidence-based medicine assessment. Current Pharmaceutical Design 7 (2001) 303-1325
19. Heller S.R., Amiel S.A., and Mansell P. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. Diabetes Care 22 (1999) 1607-1611
20. HOE 901/2004 Study Investigators Group. Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in type 2 diabetic patients. Diabetic Medicine 20 (2003) 545-551
21. Kalfhaus J., and Berger M. Insulin treatment with preprandial injections of regular insulin in middle-aged type 2 diabetic patients. A two years observational study. Diabetes and Metabolism 26 (2000) 197-201
22. Kotsanos J.G., Vignati L., Huster W., Andrejasich C., Boggs M.B., Jacobson A.M., Marrero D., Mathias S.D., Patrick D., Zalani S., and Anderson J. Health-related quality-of-life results from multinational clinical trials of insulin lispro. Assessing benefits of a new diabetes therapy. Diabetes Care 20 (1997) 948-958
23. LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: Role of metabolic and genetic abnormalities. American Journal of Medicine 113 Suppl. 6A (2002) 3-11
24. Li Y., Xu W., Liao Z., Yao B., Chen X., Huang Z., Hu G., and Weng J. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 27 (2004) 2597-2602
25. Mäkimattila S., Nikkilä K., and Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia 42 (1999) 406-412
26. Milicevic Z., Raz I., Strojek K., Skrha J., Tan M.H., Wyatt J.W., Beattie S.D., and Robbins D.C. The HEART2D Study: Hyperglycemia and its effect after acute myocardial infarction (MI) on cardiovascular (CV) outcomes in patients with type 2 diabetes. Abstract 2650. Diabetes and Metabolism 29 4S (2003) 339
27. Monnier L., Lapinski H., and Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c). Diabetes Care 26 (2003) 881-885
28. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., Kojima Y., Furuyoshi N., and Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Research and Clinical Practice 28 (1995) 103-117
29. Reviriego J., and Millan M. Health-related quality of life and insulin lispro. A naturalistic approach. Diabetes Care 21 (1998) 1203-1204
30. Riddle M.C., Rosenstock J., Gerich J., and Insulin Glargine 4002 Study Investigators. The treat-to-target trial: Randomised addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
31. Roach P., Trautmann M., Arora V., Sun B., Anderson J.H., and and the Mix 50 Study Group. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro Mix 25 and insulin lispro Mix 50. Clinical Therapeutics 21 (1999) 523-534
32. Rosenstock J., Park G., Zimmerman J., and U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 23 (2000) 1137-1142
33. Rosenstock J., Schwartz S.L., Clark Jr. C.M., Park G.D., Donley D.W., and Edwards M.B. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24 (2001) 631-636
34. Ross S.A., Zinman B., Campos R.V., Strack T., and Canadian Lispro Study Group. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clinical and Investigative Medicine 24 (2001) 292-298
35. Sheetz M.J., and King G.L. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. Journal of the American Medical Association 288 (2002) 2579-2588
36. Skyler J. Approach to hyperglycemia in the patient with diabetes mellitus; therapeutic objectives in type I diabetes. In: Humes H.D., DuPont H.L., et al. (Eds). Kelley's textbook of intern medicine (2000), Lippincott Williams & Wilkins, Philadelphia 2635-2648
37. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., Hadden D., Turner R.C., and Holman R.R. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. British Medical Journal 321 (2000) 405-412
38. Temelkova-Kurktschiev T.S., Koehler C., Henkel E., Leonhardt W., Fuecker K., and Hanefeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 23 (2000) 1830-1834
39. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
40. Yki-Järvinen H., Dressler A., Ziemen M., and HOE 901/300s Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 23 (2000) 1130-1136